Success Metrics

Active Trials

2(40%)

Phase Distribution

Ph early_phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

5(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Detailed Status

Not yet recruiting3

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 15 (100.0%)

Trials by Status

recruiting240%

not_yet_recruiting360%

Recent Activity

2 active trials

Showing 5 of 5

recruitingearly_phase_1

Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection

NCT06982547

not_yet_recruitingearly_phase_1

Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT06970951

Clinical Trials (5)

Showing 5 of 5 trials

NCT07000682Early Phase 1

The Clinical Study on the Treatment of SSc With UTAA91 Injection.

Recruiting

NCT07001956Early Phase 1

The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection

Recruiting

NCT06982534Early Phase 1

Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

Not Yet Recruiting

NCT06982547Early Phase 1

Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection

Not Yet Recruiting

NCT06970951Early Phase 1

Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5